PSMA-PET
Phase 3Small molecule
PSMA-PET is one of 24 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Mekinist
NovartisPreclinical
PSMA-PET
RRegion Västerbotten
Phase 3
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Prednisone/prednisolone
RochePreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Naropin
FFresenius Kabi Oncology Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PSMA-PET. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRegion Västerbotten